Squarepoint
FLNA

Squarepoint’s Filana Therapeutics FLNA Stock Holding History

Squarepoint’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,300
Closed -$52.1K – 4873
2025
Q4 		$52.1K Hold
26,300
– – ﹤0.01% 4124
2025
Q3 		$76.5K Hold
26,300
– – ﹤0.01% 4164
2025
Q2 		$47.6K Sell
26,300
-3,200
-11% -$5.69K ﹤0.01% 4311
2025
Q1 		$44.3K Sell
29,500
-39,000
-57% -$98.4K ﹤0.01% 4360
2024
Q4 		$162K Buy
+68,500
New +$1.2M ﹤0.01% 4550

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Squarepoint's FLNA Position: Q4 2025 in Review

Squarepoint sold out of Filana Therapeutics (FLNA) in Q4 2025, closing a stake of 12,396 shares — an estimated $39.7K sold.

Squarepoint first reported a position in FLNA in Q2 2015 and held it in 14 quarters. The position peaked at $2.33M in Q1 2021. 107 funds tracked by Wall St. Rank hold FLNA as of Q4 2025.

  • Squarepoint reported no remaining Filana Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 12,396 Filana Therapeutics shares in Q4 2025, an estimated $39.7K.
  • Squarepoint first reported a position in Filana Therapeutics in Q2 2015 and held it in 14 quarters.
  • Squarepoint's Filana Therapeutics position peaked at $2.33M in Q1 2021.
  • 107 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.